Clinical Trials on Hyperlipemia in Norway

Total 20 results

Oslo University Hospital
University of Oslo

Completed

Low Carbohydrate Diet - Effect on Plasma Lipids and Metabolic Markers

Overweight and Obesity | Type IIb Hyperlipidaemia | Hypercholesterolemia Aggravated

Norway
National Institute of Nutrition and Seafood Research...
The Research Council of Norway

Completed

Lean Seafood Intake and Postprandial Metabolism (LeSIP)

Glucose Metabolism Disorders | Metabolic Diseases | Nutrition Disorders | Hyperlipidemias | Nutritional and Metabolic Diseases

Norway
Oslo University Hospital
Pharmalogica; Wearnes Biotech @ Medicals; Beijing Peking University WBL Biotech...

Completed

The Effect of Hypocol® on Lipids in Subjects With Mild Hypercholesterolemia and Mildly Elevated Blood Glucose

Glucose Metabolism Disorders | Hyperlipidemia

Norway
Shionogi
Integrium

Completed

A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia

Combined Hyperlipidemia

United States
Amgen

Completed

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia (OSLER-2)

Hyperlipidemia and Mixed Dyslipidemia

United States, Canada, Denmark, France, Italy, Belgium, Czechia, Taiwan, Japan, Switzerland, Germany, United Kingdom, Korea, Republic of, Hong Kong, Netherlands, New Zealand, South Africa, Australia, Spain, Austria, Hungary, Russian... and more
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 (GAUSS-3)

Hyperlipidemia

Canada, Denmark, France, United States, Czechia, New Zealand, Australia, South Africa, Italy, United Kingdom, Netherlands, Germany, Norway
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins (SPIRE-SI)

Hyperlipidemia

United States, Canada
Amgen

Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels (MENDEL)

Hyperlipidemia

United States, Denmark, Australia, Belgium, Canada
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2 (GAUSS-2)

Hyperlipidemia

United States, Denmark, Belgium, Germany, Hong Kong, Netherlands, France, Australia, Canada, South Africa, United Kingdom, Spain, Poland, Switzerland
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-LL)

Hyperlipidemia

Finland, Netherlands, United States, Canada, Sweden, Korea, Republic of, Singapore, Czechia, Poland, United Kingdom, Puerto Rico, Norway
Pfizer

Completed

A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol

Hyperlipidemia

United States, Germany, Norway, Belgium, Korea, Republic of, Mexico, Sweden, United Kingdom
Amgen

Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 (MENDEL-2)

Hyperlipidemia

United States, Denmark, Taiwan, Korea, Republic of, Australia, Belgium, Canada, South Africa, France, Turkey
Amgen

Completed

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 (LAPLACE-2)

Hyperlipidemia

United States, Denmark, France, Italy, Czechia, Taiwan, Switzerland, Korea, Republic of, Germany, Hong Kong, Netherlands, Australia, Belgium, Canada, Hungary, South Africa, Russian Federation, Spain, United Kingdom, Sweden, Mexico
Pfizer

Completed

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events (SPIRE-HR)

Hyperlipidemia

Korea, Republic of, United States, Australia, Germany, Poland, Canada, Italy, Hong Kong, Czech Republic
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events (SPIRE-LDL)

Hyperlipidemia

United States, Spain, Taiwan, United Kingdom, Canada, Mexico, France, Hungary, Lithuania, Colombia, Romania, Russian Federation
Amgen

Completed

Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 (RUTHERFORD-2)

Hyperlipidemia

Canada, France, Netherlands, United Kingdom, New Zealand, South Africa, Spain, United States, Australia, Germany, Sweden, Hong Kong, Switzerland, Norway
Pfizer

Completed

Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia

Hyperlipidemia | Hypercholesterolemia, Familial

Australia, Canada, United States, France, South Africa, Sweden, Norway, Denmark, Iceland
Poznan University of Medical Sciences

Completed

Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients

Metabolic Syndrome | Diabetes Mellitus Type 2 | Hyperlipidemia | Renal Failure Chronic Requiring Hemodialysis

Poland
Bayer

Completed

Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia (LUTECIA)

Erectile Dysfunction

Israel, Italy, Colombia, Spain, Belgium, Finland, Mexico, Germany, South Africa, Netherlands, Norway, Peru, Sweden
AstraZeneca

Completed

European Study of Cardiovascular Risk (EURIKA)

Smoking | Hypertension | Obesity | Diabetes | Hyperlipidemia | Cardiovascular Risk Factors

Sweden, France, Russian Federation, Spain, Turkey, United Kingdom, Germany, Norway, Austria, Belgium, Switzerland, Greece

Clinical Trials on Hyperlipemia in Norway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations